Cell therapy in Parkinson's disease – stop or go?
- 1 May 2001
- journal article
- Published by Springer Nature in Nature Reviews Neuroscience
- Vol. 2 (5) , 365-369
- https://doi.org/10.1038/35072572
Abstract
The results of the first double-blind placebo-controlled trial using grafts of embryonic tissue to treat Parkinson's disease have aroused widespread interest and debate about the future of cell replacement therapies. What are the key issues that need to be resolved and the directions in which this technology is likely to develop?Keywords
This publication has 46 references indexed in Scilit:
- Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line—derived neurotrophic factor in patients with Parkinson's diseaseJournal of Neurosurgery, 2000
- Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's DiseaseNew England Journal of Medicine, 1999
- Sequential bilateral transplantation in Parkinson's disease: Effects of the second graftBrain, 1999
- Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's diseaseAnnals of Neurology, 1997
- Clinical correlates of {18F}fluorodopa uptake in five grafted Parkinsonian patientsAnnals of Neurology, 1995
- NIH Neural Transplantation FundingScience, 1994
- Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and researchZeitschrift für Neurologie, 1994
- Core assessment program for intracerebral transplantations (CAPIT)Movement Disorders, 1992
- Open Microsurgical Autograft of Adrenal Medulla to the Right Caudate Nucleus in Two Patients with Intractable Parkinson's DiseaseNew England Journal of Medicine, 1987
- Brain Grafts Reduce Motor Abnormalities Produced by Destruction of Nigrostriatal Dopamine SystemScience, 1979